inhibikase.com/news/press-r...
Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease
Inhibikase announces that they will empl... - Cure Parkinson's
Inhibikase announces that they will employ the new alpha-synuclein seed amplification assay biomarker in its ongoing Phase IIa trial
2 Replies
•
Great news!
I just heard about this today. Sounds promising !
Not what you're looking for?
You may also like...
Phase 3 Positive Topline Results for Tavapadon
Parkinson’s Disease
https://investors.cerevel.com/news-releases/news-release-details/cerevel-ther
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases 2022 (TUDCA)
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases...
Dr. Milto Werner, Inhibikase
several posts regarding the progress of trials conducted by Inhibikase. Here's one of several...
Another potential PD therapeutic drug?
to get on with the clinical trials
https://www.alzforum.org/therapeutics/inzomelid
Molecular chaperones for removing misfolded AS
hoping to provide new molecular targets for therapeutic interventions to thwart the disease...
Bayer reports positive early data for Parkinson’s cell therapy
Potential disease-modifying therapy enters Phase 2
Vitamin C + Omega 3 Fish Oil Combo 
Uric Acid: A Double Edged Sword
